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COPD: Optimizing Treatment
Abstract
A guideline update and an expanded armamentarium have many physicians wondering how best to treat
patients with COPD. Chronic obstructive pulmonary disease (COPD) carries a high disease burden. In
2012, it was the 4th leading cause of death worldwide.1,2 In 2015, the World Health Organization updated
its Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, classifying patients with
COPD based on disease burden as determined by symptoms, airflow obstruction, and exacerbation
history.3 These revisions, coupled with expanded therapeutic options within established classes of
medications and new combination drugs to treat COPD (TABLE 1),3-6 have led to questions about
interclass differences and the best treatment regimen for particular patients.
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A guideline update and an expanded armamentarium
have many physicians wondering how best to treat
patients with COPD. Here’s help.
Practice
recommendations
› Individualize treatment
regimens based on
severity of symptoms and risk
for exacerbation, prescribing
short-acting beta2-agonists, as
needed, for all patients with
chronic obstructive
pulmonary disease
(COPD). A
› Limit use of inhaled
long-acting beta2-agonists to
the recommended dosage;
higher doses do not lead
to better outcomes. A
Strength of recommendation (SOR)
IMAGE: © Joe gorman

A Good-quality patient-oriented
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evidence

B Inconsistent or limited-quality
patient-oriented evidence

C Consensus, usual practice,
opinion, disease-oriented
evidence, case series

C

hronic obstructive pulmonary disease (COPD) carries
a high disease burden. In 2012, it was the 4th leading cause of death worldwide.1,2 In 2015, the World
Health Organization updated its Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines, classifying patients with COPD based on disease burden as determined by
symptoms, airflow obstruction, and exacerbation history.3
These revisions, coupled with expanded therapeutic options
within established classes of medications and new combination drugs to treat COPD (TABLE 1),3-6 have led to questions
about interclass differences and the best treatment regimen
for particular patients.
Comparisons of various agents within a therapeutic
class and their impact on lung function and rate of exacerbations address many of these concerns. In the text and
tables that follow, we present the latest evidence highlighting differences in dosing, safety, and efficacy. We also include the updated GOLD classifications, evidence of efficacy
for pulmonary rehabilitation, and practical implications of
these findings for the optimal management of patients
with COPD.
But first, a word about terminology.
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Understanding COPD
COPD is a chronic lung disease characterized by progressive airflow limitation, usually measured by spirometry (TABLE 2 ),3 and
chronic airway inflammation. Emphysema
and chronic bronchitis are often used synonymously with COPD. In fact, there are important differences.
Individuals with chronic bronchitis do
not necessarily have the airflow limitations
found in those with COPD. And patients with
COPD develop pathologic lung changes beyond the alveolar damage characteristic of
emphysema, including airway fibrosis and
inflammation, luminal plugging, and loss of
elastic recoil.3
The medications included in this review
aim to reduce both the morbidity and mortality associated with COPD. These drugs can
also help relieve the symptoms of patients
with chronic bronchitis and emphysema, but
have limited effect on patient mortality.

Short- and long-acting
beta2-agonists

Bronchodilator therapy with beta2-agonists
improves forced expiratory volume in one
second (FEV1) through relaxation of airway
smooth muscle. Beta2-agonists have proven
to be safe and effective when used as needed
or scheduled for patients with COPD.7
Inhaled short-acting beta2-agonists
(SABAs) improve FEV1 and symptoms within 10 minutes, with effects lasting up to 4 to
6 hours; long-acting beta2-agonists (LABAs)
have a variable onset, with effects lasting 12 to
24 hours.8 Inhaled levalbuterol, the last SABA
to receive US Food and Drug Administration
approval, has not proven to be superior to
conventional bronchodilators in ambulatory
patients with stable COPD.3 In clinical trials,
however, the slightly longer half-life of the
nebulized formulation of levalbuterol was
found to reduce both the frequency of administration and the overall cost of therapy
in patients hospitalized with acute exacerbations of COPD.9,10
Recently approved LABAs
Clinical trials have studied the safety and
efficacy of newer agents vs older LABAs in

patients with moderate to severe COPD.
Compared with theophylline, for example,
formoterol 12 mcg inhaled every 12 hours
for a 12-month period provided a clinically significant increase of >120 ml in FEV1
(P=.026).11 Higher doses of formoterol did not
provide any additional improvement.
In a trial comparing indacaterol and
tiotropium, an inhaled anticholinergic, both
treatment groups had a clinically significant
increase in FEV1, but patients receiving indacaterol achieved an additional increase of
40 to 50 mL at 12 weeks.12
Exacerbation rates for all LABAs range
from 22% to 44%.5,12,13 In a study of patients
receiving formoterol 12 mcg compared with
15-mcg and 25-mcg doses of arformoterol,
those taking formoterol had a lower exacerbation rate than those on either strength of
arformoterol (22% vs 32% and 31%, respectively).10 In various studies, doses greater
than the FDA-approved regimens for indacaterol, arformoterol, and olodaterol did not
result in a significant improvement in either
FEV1 or exacerbation rates compared with
placebo.5,12,14
Studies that assessed the use of rescue
medication as well as exacerbation rates in
patients taking LABAs reported reductions
in the use of the rescue drugs ranging from
0.46 to 1.32 actuations per day, but the findings had limited clinical relevance.5,13 With
the exception of indacaterol and olodaterol—
both of which may be preferable because of
their once-daily dosing regimen—no significant differences in safety and efficacy among
LABAs have been found.5,12,13

Exacerbation
rates for all
long-acting
beta2-agonists
range from 22%
to 44%.

Long-acting inhaled
anticholinergics
Inhaled anticholinergic agents (IACs) can
be used in place of, or in conjunction with,
LABAs to provide bronchodilation for up to
24 hours.3 The introduction of long-acting
IACs dosed once or twice daily has the potential to improve medication adherence over
traditional short-acting ipratropium, which
requires multiple daily doses for symptom
control. Over 4 years, tiotropium has been
shown to increase time to first exacerbation
by approximately 4 months. It did not, howc o nti n u e d o n pa ge 6 1 7
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TABLE 1

COPD: Assessing newer inhaled treatments3-6
Drug/dose (trade name)

Dosing
frequency
(hours)

Evidence

12

Evidence level not assessed in current guidelines

LABAs
Arformoterol
15 mcg/2 mL solution for
nebulization (Brovana)

Nebulized arformoterol MDI resulted in a clinically
significant higher % change in FEV1 vs salmeterol
Slightly higher exacerbation rates with arformoterol
than with formoterol

Indacaterol DPI 75 mcg
(Arcapta Neohaler)

24

Bronchodilator effect greater than salmeterol and
formoterol; similar to tiotropium
Decreases breathlessness and exacerbations, improves
overall health status

Long-acting IACs
Aclidinium bromide
400 mcg DPI (Tudorza
Pressair)

12

Evidence level not determined in current guidelines, but
statement notes that aclidinium is similar to tiotropium
for lung function and shortness of breath

Tiotropium
17 mcg DPI (Spiriva
Handihaler)

24

Reduces exacerbations and hospitalizations, improves
symptoms and effectiveness of pulmonary rehabilitation

Umeclidinium bromide
62.5 mcg DPI (Incruse Ellipta)

24

Not assessed in current guidelines; active comparator
trials pending
Compared with placebo, umeclidinium resulted in
clinically significant improvements in FEV1

Combinations
ICS + LABA

24

Fluticasone + vilanterol
100/25 DPI
(Breo Ellipta)

ICS + a LABA or long-acting IAC is more effective than
individual components in improving lung function and
health status in patients with moderate to very severe
COPD
Combination therapy is associated with an increased
risk of pneumonia, but with no other significant
adverse effects

LABA + IAC
Umeclidinium + vilanterol
62.5/25 DPI
(Anoro Ellipta)

24

Not assessed in current guidelines
Product improved lung function vs monotherapy with
vilanterol

COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; IAC, inhaled anticholinergic agent; ICS, inhaled
corticosteroid; LABA, long-acting beta2-agonist; MDI, metered dose inhaler (aerosol).

ever, significantly reduce the number of exacerbations compared with placebo.15
Long-term use of tiotropium appears to
have the potential to preserve lung function.
In one trial, it slowed the rate of decline in
FEV1 by 5 mL per year, but this finding lacked
clinical significance.13 In clinical trials of pa-
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tients with moderate to severe COPD, however, once-daily tiotropium and umeclidinium
provided clinically significant improvements
in FEV1 (>120 mL; P<.01), regardless of the
dose administered.6,16 In another trial, patients taking aclidinium 200 mcg or 400 mcg
every 12 hours did not achieve a clinically sig-
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TABLE 2

GOLD classification of severity of airflow limitations3
In patients with FEV1/FVC <0.70
Class 1

Mild

FEV1 >80% predicted

Class 2

Moderate

FEV1 >50% to <80% predicted

Class 3

Severe

FEV1 >30% to <50% predicted

Class 4

Very severe

FEV1 <30% predicted

FEV1, forced expiratory volume in one second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive
Lung Disease.

Long-acting
inhaled
anticholinergic
agents—when
used in
combination
with LABAS—
have a positive
effect on FEV1,
but their effect
on exacerbation
rates has
not been
established.

nificant improvement in FEV1 compared with
placebo.17
In patients with moderate to severe
COPD, the combination of umeclidinium/
vilanterol, a LABA, administered once daily
resulted in a clinically significant improvement in FEV1 (167 mL; P<.001) vs placebo—but was not significantly better than
treatment with either agent alone.18
Few studies have evaluated time
to exacerbation in patients receiving
aclidinium or umeclidinium. In comparison to salmeterol, tiotropium reduced the time to first exacerbation by
42 days at one year (hazard ratio=0.83; 95%
confidence interval [CI], 0.77-0.9; P<.001).19
The evidence suggests that when used in
combination with LABAs, long-acting IACs
have a positive impact on FEV1, but their
effect on exacerbation rates has not been
established.

Combination therapy
with steroids and LABAs
The combination of inhaled corticosteroids
(ICS) and LABAs has been found to improve
FEV1 and symptoms in patients with moderate to severe COPD more than monotherapy
with either drug class.20,21 In fact, ICS alone
have not been proven to slow the progression
of the disease or to lower mortality rates in
patients with COPD.22
Fluticasone/salmeterol demonstrated a
25% reduction in exacerbation rates compared with placebo (P<.0001), a greater reduction than that of either drug alone.20 A
retrospective observational study comparing fixed dose fluticasone/salmeterol with

618

budesonide/formoterol reported a similar
reduction in exacerbation rates, but the number of patients requiring the addition of an
IAC was 16% lower in the latter group.23
The combination of fluticasone/vilanterol has the potential to improve adherence,
given that it is dosed once daily, unlike other
COPD combination drugs. Its clinical efficacy
is comparable to that of fluticasone/salmeterol after 12 weeks of therapy, with similar
improvements in FEV1,24 but fluticasone/
vilanterol is associated with an increased risk
of pneumonia.3
Chronic use of oral corticosteroids
Oral corticosteroids (OCS) are clinically indicated in individuals whose symptoms continue
despite optimal therapy with inhaled agents
that have demonstrated efficacy. Such patients
are often referred to as “steroid dependent.”
While OCS are prescribed for both their
anti-inflammatory activity and their ability
to slow the progression of COPD,25,26 no welldesigned studies have investigated their benefits for this patient population. One study
concluded that patients who were slowly
withdrawn from their OCS regimen had no
more frequent exacerbations than those who
maintained chronic usage. The withdrawal
group did, however, lose weight.27
GOLD guidelines do not recommend
OCS for chronic management of COPD due
to the risk of toxicity.3 The well-established
adverse effects of chronic OCS include hyperglycemia, hypertension, osteoporosis,
and myopathy.28,29 A study of muscle function
in 21 COPD patients receiving corticosteroids
revealed decreases in quadriceps muscle
strength and pulmonary function.30 Daily use
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TABLE 3

Recommended therapies based on GOLD classification3
Category

Characteristics

First-line therapies

A (Class 1 and 2)

Low risk, less symptoms

Pulmonary rehabilitation
and
short-acting IAC
or
SABA

B (Class 1 and 2)

Low risk, more symptoms

Therapies for category A
and
long-acting IAC
or
LABA

C (Class 3 and 4)

High risk, less symptoms

Therapies for category A
and
ICS + LABA
or
long-acting IAC

D (Class 3 and 4)

High risk, more symptoms

Therapies for category A
and
ICS + LABA
and/or
long-acting IAC
and/or

In one study,
patients slowly
withdrawn
from oral
corticosteroids
had no more
frequent
exacerbations
than those who
maintained
chronic usage.

PDE-4 inhibitor
GOLD, Global Initiative for Chronic Obstructive Lung Disease; IAC, inhaled anticholinergic; ICS, inhaled corticosteroid; LABA,
long-acting beta2-agonist; PDE-4, phosphodiesterase-4; SABA, short-acting beta2-agonist.

of OCS will likely result in additional therapies
to control drug-induced conditions, as well—
another antihypertensive secondary to fluid
retention caused by chronic use of OCS in patients with high blood pressure, for example,
or additional medication to control elevated
blood glucose levels in patients with diabetes.

Phosphodiesterase-4 inhibitors
The recommendation for roflumilast in patients with GOLD Class 2 to 4 symptoms remains unchanged since the introduction of this
agent as a treatment option for COPD.3 Phosphodiesterase-4 (PDE-4) inhibitors such as
roflumilast reduce inflammation in the lungs

jfponline.com

and have no activity as a bronchodilator.31,32
Roflumilast has been shown to improve FEV1 in patients concurrently receiving a long-acting bronchodilator and to
reduce exacerbations in steroid-dependent patients, a recent systematic review of
29 PDE-4 trials found.33 Patients taking roflumilast, however, suffered from more adverse
events (nausea, appetite reduction, diarrhea,
weight loss, sleep disturbances, and headache) than those on placebo.33

Antibiotics
GOLD guidelines do not recommend the use
of antibiotics for patients with COPD, except
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Patients with
limited mobility
can benefit from
non-exercise
components of
pulmonary
rehabilitation.

to treat acute exacerbations.1 However, recent
studies suggest that routine or pulsed dosing
of prophylactic antibiotics can reduce the
number of exacerbations.34-36 A 2013 review
of 7 studies determined that continuous antibiotics, particularly macrolides, reduced
the number of COPD exacerbations in patients with a mean age of 66 years (odds ratio
[OR]=0.55; 95% CI, 0.39-0.77).37
A more recent trial randomized 92 patients with a history of ≥3 exacerbations in the
previous year to receive either prophylactic
azithromycin or placebo daily for 12 months.
The treatment group experienced a significant decrease in the number of exacerbations
(OR=0.58; 95% CI, 0.42-0.79; P=.001).38 This
benefit must be weighed against the potential development of antibiotic resistance and
adverse effects, so careful patient selection is
important.

Pulmonary rehabilitation
has proven benefits
GOLD, the American College of Chest Physicians, the American Thoracic Society, and the
European Respiratory Society all recommend
pulmonary rehabilitation for patients with
COPD.39-41 In addition to reducing morbidity
and mortality rates—including a reduction
in number of hospitalizations and length of
stay and improved post-discharge recovery—
pulmonary rehabilitation has been shown to
have other physical and psychological benefits.42 Specific benefits include improved
exercise capacity, greater arm strength and
endurance, reduced perception of intensity of breathlessness, and improved overall
health-related quality of life.
Key features of rehab programs
Important components of pulmonary rehabilitation include counseling on tobacco
cessation, nutrition, education—including
correct inhalation technique—and exercise
training. There are few contraindications to
participation, and patients can derive benefit
from both its non-exercise components and
upper extremity training regardless of their
mobility level.
A 2006 Cochrane review concluded that
an effective pulmonary rehabilitation pro-
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gram should be at least 4 weeks in duration,43
and longer programs have been shown to
produce greater benefits.44 However, there
is no agreement on an optimal time frame.
Studies are inconclusive on other specific aspects of pulmonary rehab programs, as well,
such as the number of sessions per week,
number of hours per session, duration and
intensity of exercise regimens, and staff-topatient ratios.
z Home-based exercise training may
produce many of the same benefits as a formal pulmonary rehabilitation program. A
systematic review found improved quality of life and exercise capacity associated
with patient care that lacked formal pulmonary rehabilitation, with no differences between results from home-based training and
hospital-based outpatient pulmonary rehabilitation programs.45
Given the lack of availability of formal rehab programs in many communities, homebased training for patients with COPD is
important to consider.

Implications for practice
What is the takeaway from this evidencebased review? Overall, it is clear that, with the
possible exception of the effect of once-daily
dosing on adherence, there is little difference
among the therapeutic agents within a particular class of medications—and that more is
not necessarily better. Indeed, evidence suggests that higher doses of LABAs may reduce
their effectiveness, rendering them no better
than placebo. In addition, there is no significant difference in the rate of exacerbations in
patients taking ICS/LABA combinations and
those receiving IACs alone.
Pulmonary rehabilitation should be recommended for all newly diagnosed patients,
while appropriate drug therapies should be
individualized based on the GOLD symptoms/risk evaluation categories (TABLE 3 ).3
While daily OCS and daily antibiotics have
the potential to reduce exacerbation rates,
for example, the risks of adverse effects and
toxicities outweigh the benefits for patients
whose condition is stable.
Determining the optimal treatment for
a particular patient also requires an assess-
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TABLE 4

Adverse effects to consider in treatment selection
Medication class

Common adverse effects

Clinical impact

Inhaled beta2-agonists

Tachycardia, dyspepsia,
nausea, nervousness,
insomnia, tremor46,47

Adverse effects more pronounced with
SABAs vs LABAs46,47
Inhaled anticholinergics may be an
appropriate alternative to inhaled beta2agonists for patients with a history of
anxiety, arrhythmias, dilated cardiomyopathy, ischemic heart disease,
insomnia, or gastric reflux3
May be less effective in patients on
non-selective beta-blockers3

Inhaled anticholinergics

Dry mouth48

Poor systemic absorption following
inhalation48
May be preferable to inhaled
beta2-agonists for elderly patients or
those with multiple comorbidities due to
safety profile3,49
Combination of inhaled anticholinergics and smaller doses of beta2-agonists
provide improvements in FEV1 with fewer
systemic adverse effects3

Inhaled corticosteroids

Oral candidiasis and
pneumonia50

Immunocompromised patients and those
with uncontrolled diabetes are at higher
risk50

An effective
pulmonary
rehabilitation
program should
be at least
4 weeks long.

Counseling on proper administration
technique may prevent adverse effects
Continuous antibiotics

Oral corticosteroids
(daily)

GI distress (nausea, vomiting,
diarrhea)51

Crohn’s disease, IBS, and other conditions
affecting GI motility may be exacerbated
with chronic use of macrolide
antibiotics51

Antibiotic resistance51

Development of antibiotic resistance
limits choice of antimicrobials for acute
infections

Hyperglycemia, hypertension,
reduced bone mineral density,
and muscle weakness3,27-29

Well established relationship with
multiple chronic conditions that
significantly impact morbidity and
mortality3
Daily oral corticosteroid use will likely
result in additional therapies to control
drug-induced conditions3

PDE-4 inhibitors

GI discomfort, headache,
worsening depression, and
weight loss33,52

Most common adverse effects are
transient52
Depression is a common comorbid condition in patients with COPD. Pulmonary
rehabilitation has been determined to
improve symptoms of disease-associated
depression and should be considered
along with pharmacotherapy for depression in patients receiving PDE-4 inhibitors3
PDE-4 inhibitor use is associated with
weight loss; functional status and stability
should be assessed frequently to reduce
the risk of falls3,49

COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; GI, gastrointestinal; IBS, irritable
bowel syndrome; LABAs, long-acting beta2-agonists; PDE-4, phosphodiesterase-4; SABAs, short-acting beta2-agonists.
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ment of comorbidities, including potential
adverse drug effects (TABLE 4).3,27-29,33,46-52 Selection of medication should be driven by
patient and physician preference to optimize
adherence and clinical outcomes, although
cost and accessibility often play a significant
role, as well. 			
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